166 related articles for article (PubMed ID: 18697257)
1. [Pathogenetic therapy of spasticity].
Kasatkin DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):80-5. PubMed ID: 18697257
[No Abstract] [Full Text] [Related]
2. [Pharmacological treatment of spasticity in multiple sclerosis].
Heinzlef O; Monteil-Roch I
Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
[TBL] [Abstract][Full Text] [Related]
3. Dantrolene: new indication. Cerebral palsy in children: uncertain clinical benefit.
Prescrire Int; 2008 Dec; 17(98):237. PubMed ID: 19422149
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic interventions for reducing spasticity in cerebral palsy.
Patel DR; Soyode O
Indian J Pediatr; 2005 Oct; 72(10):869-72. PubMed ID: 16272661
[TBL] [Abstract][Full Text] [Related]
5. Spasticity.
Rush R; Kumbhare D
CMAJ; 2015 Apr; 187(6):436. PubMed ID: 25404397
[No Abstract] [Full Text] [Related]
6. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
Pinder RM; Brogden RN; Speight TM; Avery GS
Drugs; 1977 Jan; 13(1):3-23. PubMed ID: 318989
[TBL] [Abstract][Full Text] [Related]
7. Dantrolene sodium: long-term effects in severe spasticity.
Chyatte SB; Basmajian JV
Arch Phys Med Rehabil; 1973 Jul; 54(7):311-5. PubMed ID: 4577936
[No Abstract] [Full Text] [Related]
8. [Attenuating effect of a new pharmacological agent (Dantrolene sodium) on spasticity].
Ladd HW; Gingras G; Boucher J; Kazdan N; Keenan R
Union Med Can; 1973 May; 102(5):1087-92. PubMed ID: 4576244
[No Abstract] [Full Text] [Related]
9. The effect of dantrolene sodium on spasticity in multiple sclerosis.
Gelenberg AJ; Poskanzer DC
Neurology; 1973 Dec; 23(12):1313-5. PubMed ID: 4796610
[No Abstract] [Full Text] [Related]
10. [Treatment of spasticity].
Autti-Rämö I
Duodecim; 1999; 115(8):877-85. PubMed ID: 11859520
[No Abstract] [Full Text] [Related]
11. [Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
Lipták J
Ideggyogy Sz; 2013 Nov; 66(11-12):429. PubMed ID: 24555245
[No Abstract] [Full Text] [Related]
12. The management of cerebral palsy: subjectivity and a conundrum.
Bodensteiner JB
J Child Neurol; 1996 Mar; 11(2):75-76. PubMed ID: 8881980
[No Abstract] [Full Text] [Related]
13. The effect of Dantrium on spasticity in multiple sclerosis.
Ladd H; Oist C; Jonsson B
Acta Neurol Scand; 1974; 50(4):397-408. PubMed ID: 4277694
[No Abstract] [Full Text] [Related]
14. Treatment of children with cerebral palsy.
Dai AI
J Pediatr Orthop B; 2007 Jul; 16(4):303. PubMed ID: 17527111
[No Abstract] [Full Text] [Related]
15. Efficacy of dantrolene sodium in the treatment of spasticity.
Chipman M; Kaul S; Lambie M
Dis Nerv Syst; 1974 Sep; 35(9):427-31. PubMed ID: 17894068
[TBL] [Abstract][Full Text] [Related]
16. [Spastic syndrome and main directions of its treatment].
Damulin IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(12):4-9. PubMed ID: 14763249
[No Abstract] [Full Text] [Related]
17. New approaches to managing spasticity in children with cerebral palsy.
Im D; McDonald CM
West J Med; 1997 Apr; 166(4):271. PubMed ID: 9168686
[No Abstract] [Full Text] [Related]
18. Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome.
Nisijima K; Noguti M; Ishiguro T
Biol Psychiatry; 1997 Apr; 41(8):913-4. PubMed ID: 9099421
[No Abstract] [Full Text] [Related]
19. Novel Treatment Using Intravenous Dantrolene Sodium for Postoperative Exacerbated Spasticity in Multiple Sclerosis: A Case Report.
Sturgill EL; Wittwer RL
A A Pract; 2018 Jul; 11(1):25-27. PubMed ID: 29851691
[TBL] [Abstract][Full Text] [Related]
20. Use of botulinum toxin in the treatment of ankle plantar flexor spasticity in children with cerebral palsy.
Mirska A; Cybula K; Okurowska-Zawada B; Kułak W; Dmitruk E; Okulczyk K; Kalinowska AK
J Pediatr Orthop B; 2014 Nov; 23(6):517-22. PubMed ID: 25171568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
